Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

Annals of Pharmacotherapy

Volumn 32, Issue 3, 1998, Pages 337-348

  Johnson, Michael D ^a   Campbell, Lance K ^a   Campbell, R Keith ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Troglitazone

Indexed keywords

ACARBOSE; AMIODARONE; ASTEMIZOLE; CYTOCHROME; ERYTHROMYCIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LANSOPRAZOLE; LORATADINE; METFORMIN; OMEPRAZOLE; SULFONYLUREA DERIVATIVE; TERFENADINE; THEOPHYLLINE; TRIACYLGLYCEROL; TROGLITAZONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TABLET; VERTIGO;

ANIMALS; CHROMANS; CLINICAL TRIALS; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031909945     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17046     Document Type: Review

References (48)

1. Cowie CC, Eberhardt MS, eds. Diabetes 1996 vital statistics. Alexandria, VA: American Diabetes Association, 1996:1-102.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Ohkubo Y, Kishikawa H, Arika E, Miyata T, Iasmi S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
4. American Diabetes Association. American Diabetes Association Position Statement. Implications of the Diabetes Control and Complications Trial. Clin Diabetes 1993;July/Aug:91-6.
5. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;329:977-86.
6. Keen H. Insulin resistance and the prevention of diabetes mellitus. N Engl J Med 1994;334:1226-7.
7. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
8. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
9. Harris MI. Impaired glucose tolerance in the US population. Diabetes Care 1989;12:464-74.
10. Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev 1990;6:1-27.
11. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 1990;39:283-8.
12. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Cehn YD, et al. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabetic Med 1990;7:31-4.
13. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.
14. Harris SB, Gittelsohn J, Hanley A, Barnie A, Wolver TMS, Gao J, et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 1997;20:185-7.
15. Yudkin JS. Circulating proinsulin-like molecules. J Diabetes Complications 1993;7:113-23.
16. Phillips DI, Hirst S, Clark PM, Hales CN, Osmond C. Fetal growth and insulin secretion in adult lives. Diabetologia 1994;37:592-6.
17. Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. Birth-weight and adult health outcomes in a biethnic population in the USA. Diabetologia 1994;37:624-31.
18. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-de-pendent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25:350-6.
19. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39:1056-62.
20. Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs 1995;4:1299-309.
21. Rezulin (troglitazone). Data on file: V#8. Morris Plains, NJ: Parke-Davis Division of Warner Lambert Co., 1997.
22. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-58.
23. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mostahaf L, et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994;43:447-53.
24. Suter SL, Nolan JJ, Wallace T, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemia agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
25. Oshumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioko S, Fujiwara T, et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994;135:2279-82.
26. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
27. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yokhioka T, et al. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991;40:1213-8.
28. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KJ. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin and troglitazone. Am J Physiol 1996;241(4 pt. 1):E742-7.
29. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Itabashi A, et al. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthetase activity, and β-oxidation in fructose-fed rats. Metabolism 1995;44:1626-30.
30. Lee MK, Miles PDG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994;43:1435-9.
31. Castle CK, Colca JR, Melchior GW. Lipoprotein profile characterization of the KKA mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 1992;13:307-9.
32. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996; 277:1630-41.
33. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-6.
34. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-6.
35. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
36. Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997;20:188-93.
37. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9.
38. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299-306.
39. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-23.
40. Reaven GM, Bernstein R, Davis B, Olefsky JM. Non-ketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976;60:80-8.
41. Olefsky JM, Molina JM. Insulin resistance. In: Ellenberg and Rifkin's diabetes mellitus. 4th ed. New York: Elsevier, 1990:121-53.
42. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired glucose uptake. Metabolism 1989; 38:387-95.
43. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin action, and fasting plasma glucose concentration in non-diabetic and non-insulin dependent diabetic subjects. J Clin Invest 1984; 74:1238-46.
44. Diabetes mellitus: report of a WHO study group. WHO Tech Rep Ser 1985;727:9-17.
45. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, et al. Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest 1981;68:957-69.
46. Food and Drug Administration. FDA Talk Paper T97-55: Rezulin labeling changes. November 3, 1997. Available from http://www.fda.gov/ bbs/topics/ANSWERS/ANS00831.html.
47. Food and Drug Administration. FDA Talk Paper T97-61: Patient testing and labeling strengthened for Rezulin. December 1, 1997. Available from http://www.fda.gov/bbs/topics/ANSWERS/ANS00837.html.
48. Drug topics red book 1996. Montvale, NJ: Medical Economics, Inc., 1996.